Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes

Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes

Background: Decreased insulin clearance could be a relatively upstream abnormality in obesity, metabolic syndrome, and nonalcoholic fatty liver disease. Previous studies have shown that sodium-glucose cotransporter 2 inhibitor (SGLT2i) increases insulin–C-peptide ratio, a marker of insulin clearance...

Full description

Bibliographic Details
Main Authors: Motonori Sato, Yoshifumi Tamura, Hideyoshi Kaga, Nozomu Yamasaki, Mai Kiya, Satoshi Kadowaki, Daisuke Sugimoto, Takashi Funayama, Yuki Someya, Saori Kakehi, Shuko Nojiri, Hiroaki Satoh, Ryuzo Kawamori, Hirotaka Watada
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Biomedicines
Subjects:
SGLT2 inhibitor
insulin clearance
insulin resistance
ectopic fat
hyperinsulinemic euglycemic clamp
Online Access:https://www.mdpi.com/2227-9059/9/9/1154

Internet

https://www.mdpi.com/2227-9059/9/9/1154

Similar Items